

**Ref: MHL/Sec&Legal/2024-25/107**

**March 22, 2025**

To,  
**BSE Limited**  
Scrip Code: 542650

**National Stock Exchange of India Ltd.**  
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

In continuation to our intimation dated December 09, 2024, and February 06, 2025, in connection with acquisition of Core Diagnostics Private Limited ("Core Diagnostics"), we hereby inform you of the following update, which occurred on March 21, 2025, regarding the completion of the transaction:

1. the Board of Directors has approved the allotment of equity shares of the Company on a preferential basis to Core Diagnostics (Mauritius) Pvt. Ltd., as part of the agreed purchase consideration.
2. the remaining balance of the purchase consideration has been remitted in cash to Core Diagnostics (Mauritius) Pvt. Ltd., with INR 5 crores withheld as deferred consideration to be paid subject to closing adjustments by the parties.
3. Core Diagnostics (Mauritius) Pvt. Ltd. has transferred its 100% stake in Core Diagnostics to the Company, and necessary confirmations have been received from the respective Depository Participants as part of this process.

With this, Core Diagnostics becomes a wholly owned subsidiary of the Company, effective from March 21, 2025.

Additionally, the application for listing and trading approval of the allotted equity shares, as well as necessary filings with the RBI and other authorities, will be completed within the prescribed timeline.

You are requested to take the above information on record.

Thanking you,  
Yours faithfully,

**For Metropolis Healthcare Limited**

Kamlesh C Kulkarni  
Head – Legal & Secretarial

